Radient Pharmaceuticals Corporation fka RXPC

[lakeshore555]

CIT is dead and GCDx never lived.

Radient says CIT is dead, why bother with conjecture to the contrary? Read the SEC filing.

https://www.sec.gov/Archives/edgar/data/838879/000114420412037312/v316641_10k.htm
Due to the following conditions at December 31, 2010, we decided to impair the remaining balance of our CIT asset:

• Lack of any potential future revenue;
• Lack of future cash flows;
• High cost of future clinical studies; and
• Limited time remaining on the patent.

GCDx never got the license from Radient. Why waste time on conjecture to the contrary? Read the SEC filing.

https://www.sec.gov/Archives/edgar/data/838879/000114420412054967/v325211_8ka.htm
As of October 1, 2012, GCDx has not made the required upfront payment of $280,000. Therefore the proposed GCDx licensing agreement was cancelled.